. Author manuscript; available in PMC: 2020 Nov 5.

Published in final edited form as: Am J Med. 2017 Dec 25;131(6):676–683.e2. doi: 10.1016/j.amjmed.2017.12.010

Table Three:

Model discrimination in HEAAL derivation cohort and on external validation in the DIG cohorts

	Full model (12 predictors) in HEAAL derivation cohort		DIG compatible model (8 predictors) in HEAAL derivation cohort		DIG compatible model in main DIG trial (LVEF ≤ 45%)		DIG compatible model in pooled DIG trials (all LVEF)
	c-statistic	95% CI	c-statistic	95% CI	c-statistic	95% CI	c-statistic	95% CI
Overall model	0.72	0.66–0.70	0.71	0.69–0.73	0.69	0.67–0.70	0.69	0.68–0.70
Death	0.75	0.73–0.76	0.73	0.72–0.75	0.72	0.71–0.73	0.72	0.71–0.73
HF hospitalization	0.68	0.66–0.70	0.67	0.65–0.69	0.65	0.63–0.66	0.65	0.64–0.67

HEAAL indicates Heart Failure Endpoint evaluation of Angiotensin II Antagonist Losartan trial; DIG, Digitalis Investigator Group trial; CI, confidence interval; HF, heart failure